CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Planned Network Maintenance
Starting Saturday, August 24th, 2019 beginning at 12:00 AM EDT, and ending on Saturday, August 24th, 2019 at 04:00 AM EDT.During this time there will be no access to the system including patient enrollments.
Please share this notification to the personnel who will be affected by this within your organization.
Maintenance Start: Saturday, August 24th, 2019, 12:00 AM EDT
Maintenance End: Saturday, August 24th, 2019, 04:00 AM EDT
We are sorry for any inconvenience this may cause.
Group newsletter: CCTG Connection
August 21, 2019
Senior Investigator in the Investigational New Drug ProgramPublished: August 21, 2019Category: Group updates  The Canadian Cancer Trials Group is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program. Read More |
CCTG remembers the legacy of patient representative Aldo Del ColPublished: August 21, 2019Category: News  It is with great sadness that CCTG shares the news of the passing of Aldo Del Col, a valued member of the CCTG Patient Representative Committee and the Hematology Disease Site Committee. He worked tirelessly to ensure that the patient voice was part of the design and conduct of CCTG clinical trials. Read More |
 Dr. Michael McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology at the BC Cancer Agency (BCCA), Vancouver Cancer Centre, and a Clinical Professor in the Division of Radiation Oncology and Developmental Radiotherapeutics at University of British Columbia. He works with patients with genitourinary cancers and brain tumours. He has served as Chair of BCCA’s Palliative Care Network. Read More |
August 07, 2019
 The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee. The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees Read More |
CCTG Head and Neck Executive Committee is seeking membersPublished: August 07, 2019Category: Group updates  The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to: Read More |
 The Frances A Shepherd Award will be disbursed to one to two investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be $1000 and offered twice a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply. Each applicant must submit: Read More |
Publications - CCTG Committee on Economic AnalysisPublished: August 07, 2019Category: Publications  Three new publications from the CCTG Committee on Economic Analysis
|
July 24, 2019
 BRC7 trial has been centrally activated, this is a Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker Signature-driven Analysis Activation Date: July 10, 2019 NCT Registration ID: NCT03793179 Read More |